Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report.

ABSTRACT:

Introduction

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) poses considerable treatment challenges, with disheartening odds of long-term survival. Numerous strategies exist, including non-cross-resistant combination chemoimmunotherapy regimens, autologous stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy, but some patients are not appropriate candidates or cannot sustain response to treatment. Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, has been given accelerated approval by the US Food and Drug Administration for relapsed or refractory DLBCL.

Case presentation

We present the case of a 61-year-old male diagnosed with stage 4 "double-hit" DLBCL with MYC and BCL6 rearrangement, who initially received one

SUBMITTER: Rosiecki J 

PROVIDER: S-EPMC12169811 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature